Related Experiment Video
Updated: Jun 26, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Construct, concurrent and predictive validity of the URICA: data from two multi-site clinical trials
Craig A Field1, Bryon Adinoff, T Robert Harris
1School of Social Work, Center for Social Work Research, University of Texas at Austin, Health Behavior Research and Training Institute, 1717 West 6th Street Ste 295, Austin, TX 78703, USA. craig.field@austin.utexas.edu
Drug and Alcohol Dependence
|January 23, 2009
Summary
Measuring motivation to change in addiction treatment using the URICA scale showed construct validity but limited predictive power. Increased motivation did not significantly impact treatment outcomes for drug and alcohol dependence.
Area of Science:
- Addiction Medicine
- Psychology
- Clinical Trials
Background:
- Understanding motivation to change is crucial for addiction treatment.
- Current measures of motivation need further validation in diverse patient populations.
Purpose of the Study:
- To evaluate the construct, concurrent, and predictive validity of two motivation measures: Readiness to Change (RTC) and Committed Action (CA).
- To assess the relationship between motivation and treatment outcomes in patients with drug and alcohol dependence.
Main Methods:
- Two multi-site randomized clinical trials involving 854 patients with drug or alcohol dependence.
- Utilized the University of Rhode Island Change Assessment (URICA) to derive RTC and CA scores.
- Analyzed data using confirmatory factor analysis and correlational analyses.
Main Results:
- Confirmatory factor analysis supported the URICA's factor structure.
- RTC showed significant associations with addiction severity at baseline.
- Correlations between RTC and treatment outcomes were low and not clinically significant.
Conclusions:
- The URICA demonstrates construct validity in drug- and alcohol-dependent patients.
- Evidence for the predictive validity of URICA composite scores on treatment outcome was limited.
- Motivation to change, as measured by URICA composite scores, did not significantly influence treatment retention or substance use outcomes.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:28Imaging Studies I: Kidney, Ureter, and Bladder Studies
Kidney, Ureter, and Bladder (KUB) StudiesKidney, Ureter, and Bladder (KUB) studies are standard diagnostic imaging procedures used to assess the anatomy of the urinary system. They are commonly utilized for patients experiencing abdominal pain or urinary symptoms. By using a simple X-ray of the abdomen, KUB studies can reveal structural and pathological abnormalities within the kidneys, ureters, and bladder. These studies are particularly valuable in diagnosing kidney stones, urinary...